This is also reflected in the patent portfolio with 53 per cent of Swiss biotech patents classified as world-class patents. In addition, according to the authors of the report, the pipeline of companies is filled with promising drug candidates in the preclinical and clinical research phase.
The Swiss Federal Institute of Intellectual Property (IPI) is represented in the Steering Committee of the report. In an article, IPI experts explore how patent landscape analyses can visualise trends in biotechnology.